Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TAMOXIFEN CITRATE
- Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility
- Tamoxifen Therapy for Myotubular Myopathy
- The Effects of Natesto For Treatment Of Hypogonadism
- A Study of TY-302 in Patients With Advanced Solid Tumors
- The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
- Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
- Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
- Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
- Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
- Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
- Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF
- Tamoxifen in Patients With Oesophageal Cancer
- Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
- Phase II Study of Everolimus Beyond Progression
- Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Ramipril for the Treatment of Oligospermia
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
- Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
- Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
- Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
- Tamoxifen Citrate in Patients With Breast Cancer
- 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
- Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
- SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer
- Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
- Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
- Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
- Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients
- Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
- Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
- Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
- Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
- Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
- Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
- Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
- Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
- Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
- Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
- Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
- Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
- Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
- Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
- Tamoxifen in Treatment of Acute Mania
- Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
- Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
- CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
- Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery
- Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
- Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
- Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
- Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
- Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
- Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
- Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
- Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
- Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
- Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
- Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
- Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
- Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
- Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
- Combination Chemotherapy in Treating Women With Breast Cancer
- Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Combination Chemotherapy in Treating Women With Resected Breast Cancer
- Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
- Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma
- Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
- Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
- Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
- Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
- Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
- Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
- Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer
- Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
- Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
- Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
- Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
- Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
- Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
- Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
- Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
- Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
- Combination Chemotherapy in Treating Women With Breast Cancer
- Tamoxifen in Treating Women With Breast Cancer
- Tamoxifen in Treating Patients With Primary Liver Cancer
- Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
- Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
- Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
- Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
- Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
- Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
- Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
- High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
- Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer
- Chemotherapy Plus Surgery in Treating Women With Breast Cancer
- Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
- S9630, Medroxyprogesterone in Treating Women With Breast Cancer
- Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
- High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
- Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
- S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
- Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
- Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer
- Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
- Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
- Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
- Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
- Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
- Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
- Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
- Tamoxifen in Treating Women With High-Risk Breast Cancer
- Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer
- Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer
- Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
Clinical trials list
click for details